Circulatory 25(OH)D and 1,25(OH)
1,25(OH)2D, 1,25-dihydroxyvitamin D3 (Calcitriol)
25(OH)D, 25-hydroxyvitamin D3
H&Y, Hoehn &Yahr rating scale
Hoehn & Yahr staging scale
MMSE, Mini mental state examination
MSA, Multiple system atrophy
MoCA, Montreal Cognitive Assessment
Multiple system atrophy
PD, Parkinson's disease
Parkinson's disease
UMSARS, Unified MSA Rating Scale
UPDRS, Unified PD Rating Scale.
Unified MSA rating scale
Unified PD rating scale
Vitamin D
Journal
eNeurologicalSci
ISSN: 2405-6502
Titre abrégé: eNeurologicalSci
Pays: Netherlands
ID NLM: 101667077
Informations de publication
Date de publication:
Dec 2021
Dec 2021
Historique:
received:
24
05
2021
revised:
24
08
2021
accepted:
17
09
2021
entrez:
6
10
2021
pubmed:
7
10
2021
medline:
7
10
2021
Statut:
epublish
Résumé
There is sufficient evidence to support vitamin D's noncalcemic effects and the role of vitamin D deficiency in the development of a wide range of neurological disorders. This study aimed to evaluate whether serum 25(OH)D and 1,25(OH) 2 D could be used as biomarkers to differentiate between healthy subjects (HS), multiple system atrophy (MSA) and Parkinson's disease (PD) patients of both genders. A total of 107 subjects were included in this study, divided into three groups: 1- HS ( The levels of 25(OH)D and 1,25(OH) 2 D in HS were 26.85 +/- 7.62 ng/mL and 53.63 +/- 13.66 pg/mL respectively. 25(OH)D levels were lower in both MSA and PD by 61% and 50%, respectively ( Serum 25(OH)D and 1,25(OH) 2 D could be useful biomarkers for MSA and PD. 25(OH)D and H&Y provided the highest sensitivity and group classification characteristics.
Sections du résumé
BACKGROUND AND PURPOSE
OBJECTIVE
There is sufficient evidence to support vitamin D's noncalcemic effects and the role of vitamin D deficiency in the development of a wide range of neurological disorders. This study aimed to evaluate whether serum 25(OH)D and 1,25(OH) 2 D could be used as biomarkers to differentiate between healthy subjects (HS), multiple system atrophy (MSA) and Parkinson's disease (PD) patients of both genders.
METHODS
METHODS
A total of 107 subjects were included in this study, divided into three groups: 1- HS (
RESULTS
RESULTS
The levels of 25(OH)D and 1,25(OH) 2 D in HS were 26.85 +/- 7.62 ng/mL and 53.63 +/- 13.66 pg/mL respectively. 25(OH)D levels were lower in both MSA and PD by 61% and 50%, respectively (
CONCLUSIONS
CONCLUSIONS
Serum 25(OH)D and 1,25(OH) 2 D could be useful biomarkers for MSA and PD. 25(OH)D and H&Y provided the highest sensitivity and group classification characteristics.
Identifiants
pubmed: 34611554
doi: 10.1016/j.ensci.2021.100369
pii: S2405-6502(21)00061-7
pmc: PMC8477135
doi:
Types de publication
Journal Article
Langues
eng
Pagination
100369Informations de copyright
© 2021 The Author(s).
Références
J Zhejiang Univ Sci B. 2014 Oct;15(10):923-7
pubmed: 25294382
Neurology. 2008 Aug 26;71(9):670-6
pubmed: 18725592
Brain Behav. 2018 Feb 09;8(3):e00936
pubmed: 29541546
Neurology. 2014 Sep 2;83(10):920-8
pubmed: 25098535
Parkinsonism Relat Disord. 2015 Jan;21(1):50-4
pubmed: 25466406
Neurology. 2000 Nov 14;55(9):1358-63
pubmed: 11087781
Nucl Med Commun. 2012 Oct;33(10):1048-52
pubmed: 22773150
J Neuroinflammation. 2018 Aug 31;15(1):249
pubmed: 30170624
J Parkinsons Dis. 2017;7(4):669-675
pubmed: 28984616
J Alzheimers Dis. 2014;40(2):257-69
pubmed: 24413618
Toxicol In Vitro. 2017 Sep;43:104-112
pubmed: 28627426
Mol Pathol. 2001 Dec;54(6):419-26
pubmed: 11724918
Neurology. 1997 Nov;49(5):1273-8
pubmed: 9371907
Mov Disord. 2012 Feb;27(2):264-71
pubmed: 22213340
J Chem Neuroanat. 2005 Jan;29(1):21-30
pubmed: 15589699
Ann Neurol. 2012 May;71(5):725-7; author reply 727-8
pubmed: 22522484
J Clin Invest. 1984 Oct;74(4):1540-4
pubmed: 6332830
Mov Disord. 2004 Dec;19(12):1391-402
pubmed: 15452868
Mol Endocrinol. 1997 Dec;11(13):1961-70
pubmed: 9415400
J Parkinsons Dis. 2013;3(4):547-55
pubmed: 24081441
J Parkinsons Dis. 2016;6(1):29-37
pubmed: 26756741
Proc Natl Acad Sci U S A. 1998 Mar 31;95(7):4013-8
pubmed: 9520484
Acta Neurol Scand. 2017 Dec;136(6):570-584
pubmed: 28670681
Mol Neurodegener. 2009 Dec 10;4:49
pubmed: 20003314
Mov Disord. 2015 Oct;30(12):1591-601
pubmed: 26474316
J Clin Endocrinol Metab. 2001 Feb;86(2):888-94
pubmed: 11158062
Nutrients. 2018 Nov 03;10(11):
pubmed: 30400332
Mov Disord. 2012 Apr 15;27(5):617-26
pubmed: 22508280
Mol Neurobiol. 2019 Apr;56(4):2728-2740
pubmed: 30056575
Front Neurosci. 2019 Apr 11;13:328
pubmed: 31031582
Am J Clin Nutr. 2013 May;97(5):1004-13
pubmed: 23485413
J Neurol. 2021 Aug;268(8):2703-2712
pubmed: 32162061
J Neuroimmune Pharmacol. 2017 Jun;12(2):327-339
pubmed: 27987058
J Neurol Neurosurg Psychiatry. 2018 Feb;89(2):175-184
pubmed: 28860330
Front Immunol. 2018 Mar 12;9:477
pubmed: 29593729
J Neurosci Res. 1994 Jun 1;38(2):214-20
pubmed: 8078106
Mov Disord. 2014 Jun;29(7):857-67
pubmed: 24753321
PLoS One. 2015 Aug 20;10(8):e0136468
pubmed: 26291976
Immunopharmacol Immunotoxicol. 2008;30(4):729-40
pubmed: 18686098
Neurology. 2013 Oct 22;81(17):1531-7
pubmed: 24068787
Kidney Int. 2006 Aug;70(4):654-9
pubmed: 16807549
J Neurosci Res. 2000 Nov 1;62(3):374-82
pubmed: 11054806
Mov Disord. 2019 Nov;34(11):1629-1642
pubmed: 31692132
Annu Rev Neurosci. 2003;26:81-104
pubmed: 12574495